Core Insights - Neurocrine Biosciences, Inc. has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for February 11, 2026, at 1:30 p.m. Pacific Time [1][4] - The company is focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders, with a diverse portfolio that includes FDA-approved treatments and a robust pipeline [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company dedicated to discovering and developing life-changing treatments for patients with under-addressed conditions [2] - The company's portfolio includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some products developed in collaboration with AbbVie [2] - The company has been applying its insights into neuroscience for three decades to address complex conditions and aims to ease the burden of debilitating diseases [2]

Core Insights - Neurocrine Biosciences, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 a.m. Pacific Time [1] - The presentation will be available via live webcast on the company's website, with a replay accessible approximately one hour after the event [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, Huntington's disease-related chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some treatments developed in collaboration with AbbVie [3] - Neurocrine has a robust pipeline with multiple compounds in mid- to late-phase clinical development across its core therapeutic areas, emphasizing its commitment to addressing under-addressed medical needs [3]

Conference Call and Webcast Scheduled for Tuesday, October 28 , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on October 28, 2025. The schedule for the press release and conference call / webcast is as follows: The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webca ...